NCT04354818Unknown不适用
Coronavirus Outcomes Registries in Immunocompromised Individuals Australia (CORIA): a Multisite Registry and Optional Biorepository in People With COVID-19 and Selected Conditions Affecting Immune Function
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 27
- 试验地点
- 11
- 主要终点
- percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died
研究概览
简要总结
CORIA is an observational cohort study of immunosuppressed populations who test positive for COVID-19. This includes people living with HIV, cancer, acquired immunodeficiency associated with other immunosuppressive therapy, primary immunodeficiency and recipients of a solid organ transplant. Participants will have routine clinical data collected with optional baseline collection and storage of a blood sample for storage . The study will be conducted in up to 30 sites within Australia.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presenting (in person or via telemedicine) for evaluation because they:
- •Have clinical symptoms consistent with for COVID-19:
- •Fever (≥ 37.8 °C) on examination OR patient reported fever (≥ 37.8 °C) or feverishness (felt febrile but did not take temperature) OR any of, cough, sore throat, shortness of breath, rhinorrhoea, headache, chills, generalise myalgia, malaise, fatigue, confusion, diarrhea, nausea or vomiting
- •Have been contacted because they have been identified as a contact to a confirmed case
- •Have been contacted and told they tested positive for COVID-19
- •Have one of the following conditions affecting immune function:
- •Known or suspected primary immunodeficiency, defined as a predisposition to infection associated with an apparent or presumed deficit of immune function
- •On immunosuppressive therapy
- •Treatment with immune checkpoint inhibitors within 36 months of enrolment date
- •HIV infection
- •Diagnosis of cancer within 36 months of enrolment date, excluding superficial basal cell and squamous cell carcinomas
- •Solid organ transplantation
- •For optional biobanking only, ability to provide informed consent
排除标准
- 未提供
结局指标
主要结局
percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died
时间窗: Day 28
次要结局
- percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died(3 months)
研究者
研究点 (11)
Loading locations...
相似试验
招募中
不适用
A Follow-up Study of Immune Dysregulation in Patients With COVID-19COVID-19ImmunosuppressionNCT05669248Qilu Hospital of Shandong University200
进行中（未招募）
不适用
The health burden of COVID-19 and healthcare resource utilization in EnglandCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN53375662AstraZeneca (United Kingdom)11,990,730
招募中
不适用
Study on Immune Status of Patients With COVID-19COVID-19ImmunityLife QualityNCT05682573Qilu Hospital of Shandong University500
招募中
不适用
Capturing MultiORgan Effects of COVID-19Multi-Organ DisorderCoronavirus InfectionNCT04510025University of Oxford750
已完成
不适用
Registry of Sustained Immunity to COVID-19 Among ESKD PatientsSARS-CoV-2 InfectionAnti-SARS-CoV-2 InfectionNCT04495764Davita Clinical Research2,315